vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and SILVERCORP METALS INC (SVM). Click either name above to swap in a different company.
SILVERCORP METALS INC is the larger business by last-quarter revenue ($223.8M vs $180.9M, roughly 1.2× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -1.3%, a 0.6% gap on every dollar of revenue. Over the past eight quarters, SILVERCORP METALS INC's revenue compounded faster (87.6% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.
AVNS vs SVM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $223.8M |
| Net Profit | $-1.3M | $-2.9M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | -1.3% |
| Revenue YoY | 0.7% | — |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $223.8M | ||
| Q3 25 | $177.8M | — | ||
| Q2 25 | $175.0M | $72.2M | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | $172.5M | ||
| Q3 24 | $170.4M | $114.0M | ||
| Q2 24 | $171.7M | $60.0M | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $-1.3M | $-2.9M | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-76.8M | $28.1M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | $42.1M | ||
| Q3 24 | $4.3M | $28.0M | ||
| Q2 24 | $1.8M | $13.2M | ||
| Q1 24 | $-900.0K | — |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | 30.5% | ||
| Q3 24 | 7.0% | 30.7% | ||
| Q2 24 | 3.7% | 30.0% | ||
| Q1 24 | 2.4% | — |
| Q4 25 | -0.7% | -1.3% | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | -43.9% | 39.0% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | 24.4% | ||
| Q3 24 | 2.5% | 24.5% | ||
| Q2 24 | 1.0% | 22.0% | ||
| Q1 24 | -0.5% | — |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | — |
| Total Assets | $1.1B | — |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | — | ||
| Q3 25 | $778.0M | — | ||
| Q2 25 | $776.3M | — | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $107.9M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $107.9M | ||
| Q3 25 | $14.0M | — | ||
| Q2 25 | $6.8M | $40.0M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $81.3M | ||
| Q3 24 | $23.0M | $57.7M | ||
| Q2 24 | $27.8M | $28.9M | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | $33.8M | ||
| Q2 24 | $21.9M | $17.0M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | 29.6% | ||
| Q2 24 | 12.8% | 28.3% | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | 21.0% | ||
| Q2 24 | 3.4% | 19.8% | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | 5.35× | 2.06× | ||
| Q2 24 | 15.44× | 2.19× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SVM
Segment breakdown not available.
